Zimmer Biomet Raises 2026 Outlook After Strong Second Quarter

The company’s diluted earnings per share hit $1.03 for the period ending June 30, marking a 33.8% jump compared to the same quarter last year. While adjusted diluted earnings per share remained steady at $2.07, the firm generated $447.9 million in operating cash flow, bolstered by healthy underlying market demand across its core segments.

Chairman and CEO Ivan Tornos credited the momentum to the company's ongoing commercial shifts and a robust innovation pipeline. Notable recent milestones include FDA 510(k) clearance for the next-generation ROSA Shoulder System and a $1 billion increase in anticipated share repurchases for 2026. Looking ahead, Zimmer Biomet has tightened its full-year revenue growth forecast to a range of 3.9% to 4.9%, up from previous estimates of 2.5% to 4.5%.